Ethics and consent processes associated with using therapies ‘off label’

Definition

Off-label prescribing (using a medication outside its approved/registered indication, dose, population, or route) is common and often clinically justified by evidence, but requires specific ethical and consent considerations - informing the patient that the intended use is off-label, and the reasoning/evidence basis for the recommendation
Relevant across many areas of clinical practice, particularly paediatrics (where many drugs lack paediatric-specific registration trials), palliative care, and rare disease management, where approved on-label options are often limited

Regulatory approval reflects the specific evidence submitted for a particular indication/population/dose by the sponsor, not necessarily the full extent of a drug's genuine clinical utility - many effective, evidence-supported uses remain technically off-label simply because no sponsor has pursued formal registration for that specific use, explaining why off-label use is common and often entirely appropriate rather than inherently experimental or unjustified

Explicit disclosure that a proposed treatment is off-label, alongside the evidence base supporting its use for the intended purpose, should be part of the informed consent discussion - this transparency respects patient autonomy even when the off-label use is well-established clinical practice
Documentation of the off-label nature and the clinical reasoning supports both patient understanding and medicolegal clarity

Off-label use supported by strong evidence (e.g. many established paediatric dosing practices) should still be disclosed as off-label, distinct from unproven/experimental use, which requires a different, more cautious consent conversation
Institutional or regulatory frameworks may require specific additional approval processes for certain off-label uses (e.g. hospital drug and therapeutics committee approval) beyond individual patient consent alone

Paediatric off-label prescribing (very common given limited paediatric-specific trials), palliative care off-label symptom management, informed consent disclosure obligations, distinguishing evidence-supported off-label use from genuinely experimental use

Off-label use does not mean unevidenced or inappropriate use - much off-label prescribing (particularly in paediatrics, where many drugs were never specifically trialled in children) is well-supported by clinical evidence and standard practice, but patients should still be explicitly informed of the off-label status as part of genuine informed consent, distinct from disclosure obligations for genuinely experimental treatment

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.